key: cord-0902541-322g5cl5
authors: Andreakos, Evangelos; Zanoni, Ivan; Galani, Ioanna E
title: Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control
date: 2018-11-03
journal: Curr Opin Immunol
DOI: 10.1016/j.coi.2018.10.007
sha: 823832db7072d7640a77d415f3c7e11713d0150c
doc_id: 902541
cord_uid: 322g5cl5

Lambda interferons (IFNλs, type III IFNs or interleukins-28/29) were described fifteen years ago as novel cytokines sharing structural and functional homology with IL-10 and type I IFNs, respectively. IFNλs engage a unique receptor complex comprising IFNLR1 and IL10R2, nevertheless they share signaling cascade and many functions with type I IFNs, questioning their possible non-redundant roles and overall biological importance. Here, we review the latest evidence establishing the primacy of IFNλs in front line protection at anatomical barriers, mediating antiviral immunity before type I IFNs. We also discuss their emerging role in regulating inflammation and limiting host damage, a major difference to type I IFNs. IFNλs come thus to light as dual function cytokines mediating antiviral immunity and damage control.

Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control Evangelos Andreakos 1,2 , Ivan Zanoni 3, 4 and Ioanna E Galani 1 Lambda interferons (IFNls, type III IFNs or interleukins-28/29) were described fifteen years ago as novel cytokines sharing structural and functional homology with IL-10 and type I IFNs, respectively. IFNls engage a unique receptor complex comprising IFNLR1 and IL10R2, nevertheless they share signaling cascade and many functions with type I IFNs, questioning their possible non-redundant roles and overall biological importance. Here, we review the latest evidence establishing the primacy of IFNls in front line protection at anatomical barriers, mediating antiviral immunity before type I IFNs. We also discuss their emerging role in regulating inflammation and limiting host damage, a major difference to type I IFNs. IFNls come thus to light as dual function cytokines mediating antiviral immunity and damage control.

For a long time, type I interferons (IFNs) have been considered as the primary antiviral defense system, acting in an autocrine and paracrine manner to induce resistance to infection and enhance innate and adaptive immune responses needed for viral clearance [1] . Moreover, they have attracted major interest in oncology and multiple sclerosis as biological response modifiers able to improve therapy [1] . However, although type I IFNs have been approved for diverse indications including genital warts, viral hepatitis, hairy cell leukemia and chronic myelogenous leukemia, their use in the clinic is limited due to the frequent and severe adverse effects (including flu-like disease and depression) they exhibit.

With the completion of the Human Genome Project, it became apparent that another cytokine family, termed lambda IFNs (IFNls), type III IFNs or IL-28 and IL-29, exists and shares structural homology with the interleukin (IL)-10 family and functional homology with type I IFNs [2, 3] . Similarly to type I IFNs, IFNls are triggered by infection and induce multiple antiviral responses mediating viral clearance. They also exert pleiotropic effects on the immune system, many of which highly reminiscent to these of type I IFNs. This raised the question whether IFNls and type I IFNs are redundant, and why our organism needs two IFN-based antiviral defense systems to confront infection. Here, we review the latest evidence highlighting the primacy of IFNls in antimicrobial, and in particular antiviral, immunity. We survey their unique and common biology with type I IFNs, their co-operation with type I IFNs in the fine-tuning of antimicrobial immunity and their emerging role in damage control. We also discuss their potential as novel therapeutics that exhibit the beneficial effects, but lack the pro-inflammatory activities causing side effects, of type I IFNs.

There are four IFNl members in humans, IFNl1/IL-29, IFNl2/IL-28A, IFNl3/IL-28B, IFNl4, and two (IFNl2/ IL-28A, IFNl3/IL-28B) in mice [2] [3] [4] . Much like type I IFNs, IFNls are only transiently expressed following stimulation by viruses and microbial products. These include all major respiratory (influenza and parainfluenza viruses, rhinoviruses, respiratory syncytial viruses, coronaviruses etc), gastrointestinal (rotaviruses, reoviruses, noroviruses) and hepatotropic (hepatitis B and C) viruses [2, 3, 5, 6] , intracellular and extracellular bacteria (Listeria monocytogenes, Streptococcus pneumonia, Haemophilus influenzae, Staphylococcus aureus, Salmonella enterica, Shigella sonnei and Mycobacterium tuberculosis) [7, 8, 9 ] , and numerous microbial components and synthetic ligands (imidazoquinolines, polyinosinic-polycytidylic acid, flagellin, peptidoglycan and CpG oligodeoxynucleotides) [10, 11] .

Central to IFNl production are pattern-recognition receptors (PRRs) such as toll-like receptor (TLR)3,  TLR5, TLR7/8 and TLR9, RIG-I and MDA-5 which trigger a downstream signaling cascade leading to the activation of nuclear factor kB (NF-kB) and interferon regulatory factors (IRFs). Accordingly, IFNl genes have binding sites for NF-kB, IRF1, IRF3 and IRF7 in their promoter regions similarly to type I IFNs [2, 3, 12] . Although this would suggest co-regulation, this is often not the case; IFNls exhibit a restricted pattern of expression compared to type I IFNs which are almost ubiquitously expressed. IFNls are most abundant at barrier surfaces including the respiratory and gastrointestinal tracts, and can be robustly produced by epithelia and epithelial-origin cells including hepatocytes and some immune cells [10, 11, 13, 14] . This goes beyond the ability of all cells to respond to PRR engagement, suggesting the existence of additional cell-specific epigenetic, transcriptional and post-transcriptional regulation of IFNl production. For example, RIG-I-like receptor signaling through mitochondrial antiviral signaling protein (MAVS) in peroxisomes [15] , sensing through the cytosolic DNA sensor Ku70 [16] , induction of the transcriptional coactivator Med23 [17] or presence of transcriptional repressors such as ZEB1 and BLIMP-1 [18, 19] have all been associated with IFNl production. Whether such mechanisms can broadly account for IFNl expression patterns remains to be established.

All IFNl members engage a unique heterodimeric receptor complex, the IFNLR, that comprises IFNLR1 (IFNLRA, IL-28RA), and IL10R2 (IL-10RB). IFNLR1 confers ligand specificity and enables receptor assembly, while IL10R2 is shared with IL-10 family members and is required for signaling. Binding of IFNl to IFNLR1 and IL10R2 occurs at a 1:1:1 stoichiometry compared to the 2:1:1 ratio between IL-10, IL10R1 and IL10R2 [20 ] . IFNLR stimulation leads to the activation of the tyrosine kinases JAK1 and TYK2, and the transcription factors STAT1 and STAT2 which bind to IRF9, forming the IFN-stimulated gene factor 3 (ISGF3) complex [2, 3] . ISGF3 then enters the nucleus and induces the transcription of hundreds of genes, termed IFN-stimulated genes (ISGs), that generally inhibit viral replication and spread, and exhibit broad antimicrobial functions against viral, bacterial and parasitic infections [21] . Notably, this pathway is also shared with type I IFNs, highlighting the very similar antiviral activity these two systems exhibit [22] [23] [24] . Thus, it has been difficult to segregate IFNl from type I IFN functional or transcriptional responses, with IFNl-induced genes typically representing a subset of all genes elicited by type I IFNs but exhibiting a delayed peak and longer duration [23] [24] [25] [26] .

The most striking difference between the two IFN systems is their receptor distribution. The type I IFN receptor is expressed in almost all cell types. On the contrary, the IFNLR1/IL10RB complex is expressed primarily in cells of epithelial origin and few immune cells, mainly neutrophils and subsets of dendritic cells (DCs), conferring selective IFNl responsiveness to them. This has been demonstrated for both mouse [27 ,28 ,29 ] and human neutrophils [29 ] and plasmacytoid DC (pDCs) [11, 30] , as well as human monocytederived DC [31, 32] , and mouse bone marrow-derived or lung-sorted conventional DC (cDC) of the DC2 phenotype [33] (Figure 1 ). The expression pattern of the receptors largely follows that of their ligands with human and mouse epithelial cells [2,3,13,28 ,34] , pDCs [10, 11, 30, 35, 36] , DC1 [37] and DC2 [11,28 ,36,38] cells, as well as human monocyte-derived DC [31, 32, 38, 39] and macrophages [34, 38, 40] expressing high levels of IFNls upon activation. This points to more specialized roles for IFNls in localized immune responses at epithelial barrier surfaces conferred by epithelial and immune cells. However, subtler differences also exist. For example, JAK2 phosphorylation is induced only by IFNls but not type I IFNs [15] , while other less well-described pathways may also be important for antiviral functions [41 ] , indicating the existence of distinct signalling events that remain to be characterized.

From the very first publications describing the discovery of IFNls, it became evident that IFNls exhibit potent antiviral activity [2, 3] . Treatment of infected cells in culture or experimental animals with recombinant IFNls has been effective against a very diverse range of viruses [42] [43] [44] . However, endogenous nonredundant roles of IFNls that are not compensated by type I IFNs have been difficult to establish. Important progress has recently come from the study of gastrointestinal infections where it was shown that cell responsiveness to IFNls is largely compartmentalized with IFNls acting on intestinal epithelial cells (expressing high levels of IFNLR1) and having minimal effects on lamina propria cells (expressing low levels), while type I IFNs exhibiting the opposite effects [45, 46 ] . Accordingly, it was demonstrated that rotaviruswhich infects epithelial cells -is solely controlled by IFNls while reovirus -which replicates in both epithelial and non-epithelial cells and can spread systemically-requires the co-operative action of IFNls with type I IFNs [45,46 ,47 ] . Similarly, norovirus that grows at the gastrointestinal epithelium but spreads systemically is confronted by both IFN systems [48 ] . Interestingly, IFNls can effectively clear norovirus in antibiotics-treated mice, an effect prohibited by gut commensals [49 ] , adding another level of complexity to the equation.

In the respiratory tract, such compartmentalization is less obvious. Respiratory epithelial cells express receptors for and respond to both types of IFNs, as do certain immune cell populations residing or infiltrating the lung. Moreover, although nose, bronchial and alveolar epithelial cells express high levels of IFNls following infection [34, 50] , smooth muscle cells, fibroblasts, and DCs can also do so [10, 11, 51, 52] . This suggested a degree of redundancy between the two IFN systems, supported by early work showing increased susceptibility to respiratory viral infections in mice deficient in both IFNLR1 and IFNAR1, but not in mice deficient in only IFNLR1 [23, 53, 54] . However, more recent studies have uncovered major and unique roles of IFNls in antiviral immunity in the lung. They have revealed that IFNls are induced first, at lower viral burden than type I IFNs, and act to limit initial infection spread [28 ] . This is possibly due to the propensity of airway epithelial cells to selectively produce type III IFNs [23, 55] . In line with that, it has been reported that IFNls are essential for preventing virus transmission from the upper airways to the lungs, a process that takes place early during infection [56 ] . Interestingly, IFNls lack the strong pro-inflammatory effects of type I IFNs and are rather anti-inflammatory and tissue protective. As a result, IFNLR1 À/À mice exhibit increased viral load, inflammation and host damage following infection [28 ], whereas recombinant IFNl2 treatment potently suppresses these outcomes [57] . This is also the case when mice are treated with IFNl2/3 neutralizing antibodies [58] . These data support a model where IFNls confer initial antiviral protection without provoking unnecessary inflammation, while type I IFNs come into play as a second line of defense to enhance antiviral responses at the expense of collateral damage ( Figure 2 ). This model of IFNl action is consistent with the behavior of IFNls in the gastrointestinal tract and may therefore explain their broader role in antiviral defense. Indeed, in the liver, IFNls are also important in providing protective immunity against HBC and HCV infections as demonstrated by the many IFNl gene polymorphisms linked to improved spontaneous or treatment-induced viral clearance, and the effectiveness of IFNl therapy [59] . Interestingly, this is attributed to the ability of human hepatocytes to preferentially generate and respond to IFNls similarly to respiratory epithelial cells [60] . Moreover, in the skin, IFNls are predominantly expressed over type I IFNs and are associated with reduced incidence to infections [61] .

In addition to viruses, bacterial and fungal infections can also trigger IFNl production. L. monocytogenes, S. enterica and S. sonnei as well as several bacterial ligands induce IFNls [7, 9 ] , mainly in a MyD88-dependent manner [9 ] . This is functionally important. in vitro, IFNls enhanced epithelial barrier integrity, preventing bacterial dissemination [9 ] . In vivo, in models of S. aureus or Pseudomonas aeruginosa infection, IFNLR1 À/À mice exhibited lower Lambda interferons in antiviral immunity and damage control Andreakos, Zanoni and Galani 69 bacterial loads and less pathology, although inflammatory cell infiltration was not affected [62] . Also, intranasal infection of IFNLR1 À/À mice with S. aureus led to significantly increased bacterial clearance and, at the same time, decreased proinflammatory cytokines including IL-1b in the airways [63] . Interestingly, in this study IL-1b production appeared to be regulated by proteases released by neutrophils rather than NLRP3 and capsase-1 activation. Moreover, in a model of invasive aspergillosis with Aspergillus fumigatus, IFNLR1 À/À mice developed aggravated disease, with higher fungal loads in the lungs and more severe fungal invasion [64 ] . This was largely due to IFNl-mediated STAT1 activation in neutrophils, that was shown to protect the host. Further studies are therefore needed to shed light into the wider role of IFNls in antimicrobial defenses beyond viral infections.

In sharp contrast to type I IFNs, IFNls and their receptor are not ubiquitously expressed in the immune system. Rather, IFNls are produced by pDCs [10, 11, 30, 35, 36] , cDCs (DC1 [37] and DC2 [11,28 ,36,38] ), and monocyte-derived DC [31, 32, 38, 39] and macrophages [34, 38, 40] , as earlier discussed, while IFNLR1/IL10RB is functional in neutrophils [27 ,28 ,29 ], pDCs [11, 30] , monocyte-derived DCs [31,32] and DC2 cells [33] but not other leukocytes. IFNls therefore signal on a restricted set of leukocytes, exerting selective immune modulatory functions which are only now starting to become understood.

A primary emerging activity of IFNls is the regulation of innate immunity. Contrary to type I IFNs, IFNls suppress innate pro-inflammatory responses and limit the host damaging effects associated with inflammation. This is largely due to their selective action on neutrophils, preventing their pro-inflammatory activation and functions. Thus, in the context of influenza viral infection, IFNls restrain the production of TNF, IL-1b and other tissue destructive mediators from neutrophils, while allowing effective antiviral responses to develop [28 ] . Although it is unclear whether this is a direct effect, it nevertheless shows that IFNls are critically involved in keeping inflammation under control and limiting collateral damage. In the context of chronic intestinal inflammation, IFNls act directly on neutrophils to inhibit the generation of ROS and their degranulation through a process mediated by JAK2 [29 ] . IFNls can also induce additional beneficial effects by accelerating mucosal healing [65 ] . Exogenous administration of recombinant IFNls in experimental animal models with influenza virus infection or colitis has further confirmed their regulatory and anti-inflammatory activity, and has highlighted their therapeutic potential [29 ,57] . Moreover, exogenous administration of recombinant IFNls has shown therapeutic potential in other diseases where IFNls may not be produced naturally such as collagen-induced Model of IFNl action. IFNls confer initial antiviral protection at anatomical barriers without provoking unnecessary inflammation. Type I IFNs come up as a second line of defense, following escape from IFNl control, to enhance antiviral and immunoinflammatory responses, at the expense though of collateral damage. [66 ] . In arthritis, the efficacy of IFNl treatment was attributed to the inhibitory effects of IFNls in neutrophil migration [27 ] . In arterial thrombosis, IFNl-mediated protection was due to the suppressive effects of IFNls on neutrophil-extracellular traps (NETs) formation [66 ] . This anti-inflammatory or immune-modulatory behavior of IFNls is reminiscent of the activity of IL-10 with which IFNls share sequence homology and the IL10RB subunit for signaling ( Figure 3 ).

Another major activity of IFNls is the regulation of adaptive immunity. IFNls signal on DC2 cells [31] [32] [33] and pDCs [11, 30] , of both human and mouse origin, and modulate their function. in vitro, IFNls enhance the propensity of human monocyte-derived DCs to generate Foxp3 + regulatory T cells [31, 32] . in vivo, IFNls suppress the ability of mouse DC2 cells to induce T helper 2 (Th2) and Th17 differentiation, and enhance Th1 cell development [33] . This is consistent with cell culture studies using mouse DC2 and T cells [33] , or human peripheral blood mononuclear cells (PBMC) [67] . Interestingly, a SNP in the Ifnl3 locus (rs8099917) is linked to higher IFNl3 production and Th1 skewing following PBMC stimulation with influenza virus [68] . A shift in IFNg production from NK cells is also observed but this might be indirect as neither NK cells [11, 13] nor T cells [11, 33] seem to respond to IFNls. The Th1 skewing effect of IFNls may be related to their capacity to increase the expression of the Th1 polarizing cytokine IL-12 in a context-dependent manner [33, 69] . Noteworthy, cytotoxic T cell responses may also be affected by IFNls as increased CD8 + T cell responses have been reported in IFNLR1 À/À mice following acute LCMV infection [70] .

Interestingly, in T cell-driven diseases in experimental animals IFNls are therapeutically effective. In allergic asthma, IFNls potently suppress the activation of Th2 and Th17 responses, and the development of immunopathology [33] . In autoimmune arthritis, they also inhibit the induction of Th17 and gd T cell responses and they ameliorate disease [27 ] . IFNls therefore appear to be broadly protective, in both acute and chronic inflammatory diseases, mediating immune modulatory actions aiming at restoring immunological balance and limiting direct tissue damage caused by the byproducts of host defense ( Figure 4 ).

Over the last few years IFNls have come out of the shadow of type I IFNs. They have emerged as a front line defense system mediating antiviral immunity at anatomical barriers such as the gastrointestinal and respiratory tracts. They have also emerged as novel immune regulatory cytokines with a special duty in damage control that act to maintain immunological balance and limit immunopathology. This extends beyond infections as IFNls limit inflammation and prevent host damage in diverse other diseases including colitis, autoimmune arthritis and allergic asthma.

Central to the unique biology of IFNls is their selective action on neutrophils, preventing their pro-inflammatory activation, inhibiting ROS production, degranulation and NET formation, and down regulating their migratory capacity. This is in sharp contrast to the pro-inflammatory effects of type I IFNs, which instead activate neutrophils and other leukocytes, and highlights the IL-10-like properties of IFNls that remain to be further investigated.

Lambda interferons in antiviral immunity and damage control Andreakos, Zanoni and Galani 71 This may also explain the improved safety profile IFNls exhibit in the clinic.

The dual antimicrobial and immune regulatory function of IFNls makes them particularly attractive for the treatment of infectious diseases or chronic disorders such as asthma and colitis where infections can exacerbate their severity, as IFNls can selectively up regulate antiviral responses while limiting host damaging inflammation and symptoms. It also advocates for the broader evaluation of IFNls in the fine-tuning of immunity in diseases which involve neutrophilic inflammation and alterations of the Th1/Th2/Th7 balance. Further studies towards these directions are therefore eagerly awaited. IFNls as dual function cytokines mediating antiviral activity and damage control. The schematic shows the unique and non-redundant roles of IFNls in antiviral defense, and their immune regulatory actions mediating disease protection as emerging over the last years.

E. Andreakos has received consultancy fees from Vorso Corp and in Thought Research, and grants from Novosom AG and Janssen. I. Zanoni and I. Galani declare no relevant conflict of interest.

influenza virus infection without compromising host fitness. Immunity 2017, 46:875-890 e6. This study revealed the non-redundant role of IFNls in front-line antiviral protection in the respiratory tract. It demonstrated that IFNls mediate initial antiviral defenses, before type I IFNs, without provoking unnecessary inflammation and causing damage. It also uncovered the importance of both IFN systems in the fine-tuning of neutrophil function and antiviral immunity. 

Interferons at age 50: past, current and future impact on biomedicine

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

IL-28, IL-29 and their class II cytokine receptor IL-28R

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

Lambda interferon inhibits hepatitis B and C virus replication

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo

A bacterial protein targets the BAHD1 chromatin complex to stimulate type III interferon response

Activation of type III interferon genes by pathogenic bacteria in infected epithelial cells and mouse placenta

Type III IFNs are commonly induced by bacteria-sensing TLRs and reinforce epithelial barriers during infection

Meticulous study showing that IFNls are induced by bacteria and diverse bacterial ligands

Viral infection and toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells

An important role for type III interferon (IFNlambda/IL-28) in TLR-induced antiviral activity

IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes

IFN-lambda (IFNlambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo

Expression of type III interferons (IFNlambdas) and their receptor in Sjogren's syndrome

Diverse intracellular pathogens activate type III interferon expression from peroxisomes

Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN

A systematic analysis of host factors reveals a Med23-interferon-lambda regulatory axis against herpes simplex virus type 1 replication

Regulation of IFN-lambda1 promoter activity (IFN-lambda1/IL-29) in human airway epithelial cells

Blimp-1/PRDM1 is a critical regulator of Type III Interferon responses in mammary epithelial cells

The IFN-lambda-IFN-lambdaR1-IL-10Rbeta complex reveals structural features underlying Type III IFN functional plasticity

This work unravelled the crystal structure of the IFNlR receptor and explained how the IL-10Rb chain acts as a cross-reactive but also cytokine-specific receptor. This provides broader insight into cytokine recognition by the IL-10R family

Interferon-stimulated genes: a complex web of host defenses

Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases

Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells

IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease

Role of deficient type III interferon-lambda production in asthma exacerbations

IL-4 enhances IFN-lambda1 (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra

Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection

Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC

Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand-and cell-dependent

Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells

Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages

Interferon-lambda restricts West Nile virus neuroinvasion by tightening the blood-brain barrier

Guarding the frontiers: the biology of type III interferons

Interferon-lambda: immune functions at barrier surfaces and beyond

Interferonlambdas: front-line guardians of immunity and homeostasis in the respiratory tract

IFN-lambda determines the intestinal epithelial antiviral host defense

Leukocyte-derived IFN-alpha/beta and epithelial IFN-lambda constitute a compartmentalized mucosal defense system that restricts enteric virus infections

This work demonstrated that in the gastrointestinal tract the type I and type III IFN systems are compartmentalized, with IFNls acting at the epithelial barrier and type I IFNs at the lamina propria to confer protection against viral infections

Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection

This study showed that IFNls acts synergistically with IL-22 to induce optimal antiviral responses and microbial clearance in the gastrointestinal tract

Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity

This study demonstrated the ability of IFNls to cure norovirus infections even in the absence of adaptive immunity

Commensal microbes and interferonlambda determine persistence of enteric murine norovirus infection

This report showed that commensal microbes compromise the ability of IFNls to deal with norovirus infections in the gastrointestinal tract

Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda 1) in response to influenza A infection

Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/ beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses

Rhinovirus and dsRNA induce RIG-Ilike receptors and expression of interferon beta and lambda1 in human bronchial smooth muscle cells

Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses

Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections

Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo

IFN-lambda prevents influenza virus spread from the upper airways to the lungs and limits virus transmission

IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment

The superiority of IFN-lambda as a therapeutic candidate to control acute influenza viral lung infection

Interferon-lambda and therapy for chronic hepatitis C virus infection

IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection

IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis

Bacterial pathogens activate a common inflammatory pathway through IFNlambda regulation of PDCD4

IL-1beta activation in response to Staphylococcus aureus lung infection requires inflammasome-dependent and independent mechanisms

Type III interferon is a critical regulator of innate antifungal immunity

Activation of epithelial signal transducer and activator of transcription 1 by interleukin 28 controls mucosal healing in mice with colitis and is increased in mucosa of patients with inflammatory bowel disease

This indicates that IFNls, though STAT1 activation, control proliferation of intestinal epithelial cells and accelerate mucosal healing in inflammatory bowel disease

Interferon lambda1/IL-29 and inorganic polyphosphate are novel regulators of neutrophil-driven thromboinflammation

Important study showing that IFNls suppress NET formation and arterial thrombosis through a post-transcriptional mechanism involving inhibition of autophagy

Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29)

IL-28B is a key regulator of B-and T-cell vaccine responses against influenza

IL-29 and IFNalpha differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNgamma receptor expression

IFN-lambda exerts opposing effects on T cell responses depending on the chronicity of the virus infection